Pathogenesis of muscle wasting in cancer cachexia

Targeted anabolic and anticatabolic therapies

Kimberlee Burckart, Sorin Beca, Randall Urban, Melinda Sheffield-Moore

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose of review: Cancer-related muscle loss, or cachexia, is the cause of death for approximately 2 million people worldwide and severely reduces quality of life. The degree of cachexia is inversely correlated with survival time; however, the exact mechanisms behind cancer-induced muscle wasting remain under investigation. RECENT FINDINGS: Cytokines such as tumor necrosis factor-α trigger degradatory pathways through nuclear factor-κB signaling that activate the ubiquitin-proteasome system and muscle proteolysis. Androgen treatment has been shown to reduce inflammatory cytokines and even stimulate anti-inflammatory cytokine production. Amino acid supplementation has been shown to induce muscle protein synthesis in ovarian cancer patients. Summary: Targeted anabolic therapies aimed at preventing or reversing cancer cachexia might involve the combined use of androgens and amino acids working concurrently to enhance muscle protein synthesis and reduce muscle protein breakdown. Additional focused clinical studies are needed to identify muscle-specific targets or biomarkers for defined therapeutic approaches to slow or prevent cancer cachexia. In this review, we summarize the pathogenesis of cancer-related muscle wasting and discuss potential interventions at reversing or preventing cancer-related muscle loss.

Original languageEnglish (US)
Pages (from-to)410-416
Number of pages7
JournalCurrent Opinion in Clinical Nutrition and Metabolic Care
Volume13
Issue number4
DOIs
StatePublished - Jul 2010

Fingerprint

Muscle Neoplasms
Cachexia
Muscle Proteins
Muscles
Cytokines
Androgens
Neoplasms
Amino Acids
Proteasome Endopeptidase Complex
Therapeutics
Ubiquitin
Ovarian Neoplasms
Proteolysis
Cause of Death
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Biomarkers
Quality of Life
Survival

Keywords

  • amino acids
  • androgens
  • cachexia
  • muscle atrophy F box
  • muscle-specific RINGFinger-1

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Pathogenesis of muscle wasting in cancer cachexia : Targeted anabolic and anticatabolic therapies. / Burckart, Kimberlee; Beca, Sorin; Urban, Randall; Sheffield-Moore, Melinda.

In: Current Opinion in Clinical Nutrition and Metabolic Care, Vol. 13, No. 4, 07.2010, p. 410-416.

Research output: Contribution to journalArticle

@article{ce14ad801e334840a5f128a2fdfd1ba1,
title = "Pathogenesis of muscle wasting in cancer cachexia: Targeted anabolic and anticatabolic therapies",
abstract = "Purpose of review: Cancer-related muscle loss, or cachexia, is the cause of death for approximately 2 million people worldwide and severely reduces quality of life. The degree of cachexia is inversely correlated with survival time; however, the exact mechanisms behind cancer-induced muscle wasting remain under investigation. RECENT FINDINGS: Cytokines such as tumor necrosis factor-α trigger degradatory pathways through nuclear factor-κB signaling that activate the ubiquitin-proteasome system and muscle proteolysis. Androgen treatment has been shown to reduce inflammatory cytokines and even stimulate anti-inflammatory cytokine production. Amino acid supplementation has been shown to induce muscle protein synthesis in ovarian cancer patients. Summary: Targeted anabolic therapies aimed at preventing or reversing cancer cachexia might involve the combined use of androgens and amino acids working concurrently to enhance muscle protein synthesis and reduce muscle protein breakdown. Additional focused clinical studies are needed to identify muscle-specific targets or biomarkers for defined therapeutic approaches to slow or prevent cancer cachexia. In this review, we summarize the pathogenesis of cancer-related muscle wasting and discuss potential interventions at reversing or preventing cancer-related muscle loss.",
keywords = "amino acids, androgens, cachexia, muscle atrophy F box, muscle-specific RINGFinger-1",
author = "Kimberlee Burckart and Sorin Beca and Randall Urban and Melinda Sheffield-Moore",
year = "2010",
month = "7",
doi = "10.1097/MCO.0b013e328339fdd2",
language = "English (US)",
volume = "13",
pages = "410--416",
journal = "Current Opinion in Clinical Nutrition and Metabolic Care",
issn = "1363-1950",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Pathogenesis of muscle wasting in cancer cachexia

T2 - Targeted anabolic and anticatabolic therapies

AU - Burckart, Kimberlee

AU - Beca, Sorin

AU - Urban, Randall

AU - Sheffield-Moore, Melinda

PY - 2010/7

Y1 - 2010/7

N2 - Purpose of review: Cancer-related muscle loss, or cachexia, is the cause of death for approximately 2 million people worldwide and severely reduces quality of life. The degree of cachexia is inversely correlated with survival time; however, the exact mechanisms behind cancer-induced muscle wasting remain under investigation. RECENT FINDINGS: Cytokines such as tumor necrosis factor-α trigger degradatory pathways through nuclear factor-κB signaling that activate the ubiquitin-proteasome system and muscle proteolysis. Androgen treatment has been shown to reduce inflammatory cytokines and even stimulate anti-inflammatory cytokine production. Amino acid supplementation has been shown to induce muscle protein synthesis in ovarian cancer patients. Summary: Targeted anabolic therapies aimed at preventing or reversing cancer cachexia might involve the combined use of androgens and amino acids working concurrently to enhance muscle protein synthesis and reduce muscle protein breakdown. Additional focused clinical studies are needed to identify muscle-specific targets or biomarkers for defined therapeutic approaches to slow or prevent cancer cachexia. In this review, we summarize the pathogenesis of cancer-related muscle wasting and discuss potential interventions at reversing or preventing cancer-related muscle loss.

AB - Purpose of review: Cancer-related muscle loss, or cachexia, is the cause of death for approximately 2 million people worldwide and severely reduces quality of life. The degree of cachexia is inversely correlated with survival time; however, the exact mechanisms behind cancer-induced muscle wasting remain under investigation. RECENT FINDINGS: Cytokines such as tumor necrosis factor-α trigger degradatory pathways through nuclear factor-κB signaling that activate the ubiquitin-proteasome system and muscle proteolysis. Androgen treatment has been shown to reduce inflammatory cytokines and even stimulate anti-inflammatory cytokine production. Amino acid supplementation has been shown to induce muscle protein synthesis in ovarian cancer patients. Summary: Targeted anabolic therapies aimed at preventing or reversing cancer cachexia might involve the combined use of androgens and amino acids working concurrently to enhance muscle protein synthesis and reduce muscle protein breakdown. Additional focused clinical studies are needed to identify muscle-specific targets or biomarkers for defined therapeutic approaches to slow or prevent cancer cachexia. In this review, we summarize the pathogenesis of cancer-related muscle wasting and discuss potential interventions at reversing or preventing cancer-related muscle loss.

KW - amino acids

KW - androgens

KW - cachexia

KW - muscle atrophy F box

KW - muscle-specific RINGFinger-1

UR - http://www.scopus.com/inward/record.url?scp=77954348785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954348785&partnerID=8YFLogxK

U2 - 10.1097/MCO.0b013e328339fdd2

DO - 10.1097/MCO.0b013e328339fdd2

M3 - Article

VL - 13

SP - 410

EP - 416

JO - Current Opinion in Clinical Nutrition and Metabolic Care

JF - Current Opinion in Clinical Nutrition and Metabolic Care

SN - 1363-1950

IS - 4

ER -